StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.08−0.91 (-18.24%)

Close on Nov 18, 2026Market cap $400.20MP/E –Yield –

aTYR PHARMA operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

aTYR PHARMA's operating cash flow for the twelve months ending Jun 30, 2026 was -$54.54M. For fiscal 2025 it was -$61.99M. The highest annual figure on record is -$15.30M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$61.99M–
FY2024Dec 31, 2024-$69.12M–
FY2023Dec 31, 2023-$33.22M–
FY2022Dec 31, 2022-$41.89M–
FY2021Dec 31, 2021-$33.08M–
FY2020Dec 31, 2020-$15.30M–
FY2019Dec 31, 2019-$20.01M–
FY2018Dec 31, 2018-$31.06M–
FY2017Dec 31, 2017-$42.36M–
FY2016Dec 31, 2016-$52.86M–
FY2015Dec 31, 2015-$36.80M–
FY2014Dec 31, 2014-$22.82M–
FY2013Dec 31, 2013-$17.31M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.35M–
Q1 FY2026Mar 31, 2026-$12.52M–
Q4 FY2025Dec 31, 2025-$12.20M–
Q3 FY2025Sep 30, 2025-$20.48M–
Q2 FY2025Jun 30, 2025-$13.89M–
Q1 FY2025Mar 31, 2025-$15.42M–
Q4 FY2024Dec 31, 2024-$13.13M–
Q3 FY2024Sep 30, 2024-$13.16M–
Q2 FY2024Jun 30, 2024-$20.45M–
Q1 FY2024Mar 31, 2024-$22.38M–
Q4 FY2023Dec 31, 2023-$11.06M–
Q3 FY2023Sep 30, 2023-$9.56M–
Q2 FY2023Jun 30, 2023-$12.01M–
Q1 FY2023Mar 31, 2023-$590.00K–
Q4 FY2022Dec 31, 2022-$10.37M–
Q3 FY2022Sep 30, 2022-$12.28M–
Q2 FY2022Jun 30, 2022-$9.12M–
Q1 FY2022Mar 31, 2022-$10.12M–
Q4 FY2021Dec 31, 2021-$8.09M–
Q3 FY2021Sep 30, 2021-$11.47M–
Q2 FY2021Jun 30, 2021-$7.69M–
Q1 FY2021Mar 31, 2021-$5.83M-383.1%
Q4 FY2020Dec 31, 2020-$5.40M–
Q3 FY2020Sep 30, 2020-$5.56M–
Q2 FY2020Jun 30, 2020-$6.40M–
Q1 FY2020Mar 31, 2020$2.06M–
Q4 FY2019Dec 31, 2019-$4.92M–
Q3 FY2019Sep 30, 2019-$4.25M–
Q2 FY2019Jun 30, 2019-$4.82M–
Q1 FY2019Mar 31, 2019-$6.02M–
Q4 FY2018Dec 31, 2018-$4.84M–
Q3 FY2018Sep 30, 2018-$6.46M–
Q2 FY2018Jun 30, 2018-$9.19M–
Q1 FY2018Mar 31, 2018-$10.58M–
Q4 FY2017Dec 31, 2017-$10.31M–
Q3 FY2017Sep 30, 2017-$8.89M–
Q2 FY2017Jun 30, 2017-$9.28M–
Q1 FY2017Mar 31, 2017-$13.89M–
Q4 FY2016Dec 31, 2016-$11.70M–
Q3 FY2016Sep 30, 2016-$14.69M–

More aTYR PHARMA figures

See a number that looks wrong?